| Gastrointestinal Tumor Research and Treatment | Lifetime | 12 | PL 1 | 99.86 |
| Sarcoma Diagnosis and Treatment | Lifetime | 25 | PL 1 | 99.82 |
| Gastrointestinal disorders and treatments | Lifetime | 27 | PL 1 | 99.82 |
| CAR-T cell therapy research | Lifetime | 78 | PL 1 | 99.68 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 110 | PL 1 | 99.71 |
| Cutaneous Melanoma Detection and Management | Lifetime | 31 | PL 1 | 99.65 |
| Gastric Cancer Management and Outcomes | Lifetime | 141 | PL 1 | 99.56 |
| Cardiac tumors and thrombi | Lifetime | 40 | PL 1 | 99.56 |
| Melanoma and MAPK Pathways | Lifetime | 31 | PL 1 | 99.58 |
| Vascular Tumors and Angiosarcomas | Lifetime | 29 | PL 1 | 99.50 |
| Bone Tumor Diagnosis and Treatments | Lifetime | 68 | PL 1 | 99.33 |
| Neurofibromatosis and Schwannoma Cases | Lifetime | 66 | PL 1 | 98.98 |
| Immunotherapy and Immune Responses | Lifetime | 655 | PL 3 | 98.96 |
| Soft tissue tumor case studies | Lifetime | 88 | PL 1 | 98.66 |
| Dialysis and Renal Disease Management | Lifetime | 296 | PL 1 | 98.52 |
| Nonmelanoma Skin Cancer Studies | Lifetime | 150 | PL 1 | 98.26 |
| Oral and Maxillofacial Pathology | Lifetime | 505 | PL 1 | 97.49 |
| Chronic Kidney Disease and Diabetes | Lifetime | 580 | PL 3 | 96.94 |
| Renal Diseases and Glomerulopathies | Lifetime | 927 | PL 1 | 96.17 |
| Erythropoietin and Anemia Treatment | Lifetime | 401 | PL 7 | 94.42 |
| Medical and Biological Ozone Research | Lifetime | 265 | PL 5 | 90.83 |
| Tumors and Oncological Cases | Lifetime | 916 | PL 4 | 92.53 |
| Soft tissue tumors and treatment | Lifetime | 130 | PL 1 | 92.50 |
| Tuberous Sclerosis Complex Research | Lifetime | 285 | PL 6 | 90.18 |
| Synthesis of Tetrazole Derivatives | Lifetime | 315 | PL 7 | 85.95 |
| Public health and occupational medicine | Lifetime | 280 | PL 217 | 64.52 |
| Sarcoma Diagnosis and Treatment | 2021-2025 | 3 | PL 1 | 99.86 |
| CAR-T cell therapy research | 2021-2025 | 40 | PL 1 | 99.65 |
| Cutaneous Melanoma Detection and Management | 2021-2025 | 9 | PL 1 | 99.61 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 71 | PL 1 | 99.71 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 12 | PL 1 | 99.48 |
| Bone Tumor Diagnosis and Treatments | 2021-2025 | 7 | PL 1 | 99.13 |
| Immunotherapy and Immune Responses | 2021-2025 | 38 | PL 2 | 99.33 |
| Melanoma and MAPK Pathways | 2021-2025 | 7 | PL 1 | 99.74 |
| Cardiac tumors and thrombi | 2021-2025 | 8 | PL 1 | 98.38 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 5 | PL 1 | 99.00 |
| Gastrointestinal disorders and treatments | 2021-2025 | 33 | PL 1 | 97.80 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 379 | PL 3 | 96.87 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 93 | PL 2 | 95.13 |
| Soft tissue tumor case studies | 2021-2025 | 31 | PL 1 | 93.94 |
| Oral and Maxillofacial Pathology | 2021-2025 | 191 | PL 5 | 92.16 |
| Ocular Oncology and Treatments | 2021-2025 | 95 | PL 1 | 92.48 |
| Neurofibromatosis and Schwannoma Cases | 2021-2025 | 146 | PL 1 | 91.20 |
| Musculoskeletal synovial abnormalities and treatments | 2021-2025 | 90 | PL 2 | 89.01 |
| Cancer and Skin Lesions | 2021-2025 | 236 | PL 7 | 83.55 |
| Polyomavirus and related diseases | 2021-2025 | 359 | PL 6 | 84.78 |
| Ear and Head Tumors | 2021-2025 | 450 | PL 9 | 75.26 |
| Tuberous Sclerosis Complex Research | 2021-2025 | 185 | PL 5 | 69.48 |
| Tumors and Oncological Cases | 2021-2025 | 847 | PL 12 | 62.96 |
| Soft tissue tumors and treatment | 2021-2025 | 87 | PL 1 | 60.36 |
| Synthesis of Tetrazole Derivatives | 2021-2025 | 402 | PL 4 | 30.45 |
